Description
Release form
Tablets.
Packing
50 pcs.
Pharmacological action
Phenigidine is a calcium channel blocker, a derivative of dihydropyridine. It inhibits the entry of calcium into cardiomyocytes and smooth muscle cells of blood vessels. It has antianginal and antihypertensive effects. Reduces the tone of the smooth muscles of the vessels. Expands coronary and peripheral arteries, lowers total peripheral vascular resistance, blood pressure, reduces afterload and myocardial oxygen demand.
Pharmacokinetics. When administered, phenygidine is rapidly and almost completely (more than 90%) absorbed from the gastrointestinal tract. Bioavailability is approximately 50%. The maximum plasma concentration is recorded 20-40 minutes after administration. Clinical effect onset: 20 min for oral administration, 5 min for sublingual administration. The duration of the clinical effect is 4-6 hours. The half-life is 2-4 hours. It is excreted mainly in the urine in the form of inactive metabolites. No cumulative effect.
Indications
Prevention and treatment of angina attacks arterial hypertension of various origins, hypertensive crisis.
Contraindications
Hypersensitivity to Phenigidin, cardiogenic shock, hypotension, tachycardia, acute myocardial infarction (first 8 days), heart failure, pregnancy, childhood.
Since Phenigidine is excreted in breast milk, avoid using it during lactation or stop breastfeeding during treatment
Special instructions
Special care must be taken when prescribing the drug to patients with significantly reduced blood pressure (systolic pressure below 90 mmHg), with severe heart failure or aortic stenosis.
In case of impaired liver function, careful medical monitoring of patients should be ensured, and if necessary, reduce the dose of Phenigidin.
The drug can affect the psychophysical abilities of the body, weakening attention and slowing down the response, especially while drinking alcohol.
The use of grapefruit juice during treatment with phenigidine can lead to an increase in the concentration of the drug in blood plasma and an increase in its hypotensive effect.
Taking Phenigidin may cause a false increase in the level of vanilla-mandelic acid in the urine during spectrophotometric studies, the results of determining this indicator by high pressure liquid chromatography are not distorted.
Composition
1 tablet contains phenygidine 0.01 g
excipients: potato or corn starch, milk sugar, refined sugar, calcium stearate, tween-80.
Dosage and administration of
The drug is taken orally without chewing, washing down with a small amount of liquid, regardless of food intake. Simultaneous eating slows down, but does not reduce the degree of absorption of the drug (some products affect the bioavailability of the drug). The dose is set individually. The initial dose for adults is 10 mg (1 tablet), 3-4 times a day. If necessary, the dose is gradually increased to 20 mg, 3-4 times a day. The maximum daily dose is 120 mg. To stop an attack of angina pectoris or a hypertensive crisis, the drug is used sublingually: 1 tablet of 0.01 g is chewed and placed under the tongue after some time (5-10 minutes), the drug can be swallowed with a small amount of water, while it is recommended to be in a lying position for 30-60 minutes The duration of treatment is determined by the doctor.
Side effects
Side effects occur mainly at the beginning of treatment, are usually mild and temporary. More than 1% of patients may experience headache, flushing of the skin of the face and other parts of the body, accompanied by a burning sensation (erythema, erythromegaly), palpitations, swelling of the legs (associated with vasodilation), dizziness, increased fatigue, nausea, a feeling of heaviness in the stomach, diarrhea, constipation in less than 1% of cases, shortness of breath, myalgia, tremor, irritability, paresthesia, tachycardia, arterial hypotension, skin rash and itching in less than 0.1% of patients (in some older men with prolonged therapy) are possible m Jette develop gynecomastia completely regressing after discontinuation of the drug during long-term treatment is also possible gingival hyperplasia, completely disappearing after drug withdrawal. Initial hyperglycemia, transient visual impairment, increased daily diuresis (can be regarded as a positive effect with elevated blood pressure), impaired liver function (increased transaminases, intrahepatic cholestasis), exfoliative dermatitis, photosensitivity, systemic allergic reactions, thrombocytopenic purpura, phenomena disappear after discontinuation of the drug. Due to a decrease in blood pressure, collapse may develop. A sharp decrease in blood pressure due to vasodilation is possible in patients undergoing dialysis, with malignant arterial hypertension and hypovolemia. When treating patients with stable angina pectoris within 1 hour after taking Phenigidin, pain behind the sternum may appear as an angina pectoris.
In some patients, usually at the beginning of treatment, an increase in the frequency, duration and severity of angina attacks is possible, which requires discontinuation of the drug.
Overdose
Symptoms: headache, facial flushing, prolonged systemic hypotension, bradycardia, bradyarrhythmia. In severe poisoning, collapse, oppression of the sinus node is possible. Treatment: administration of norepinephrine, intravenous administration of calcium chloride or calcium gluconate in a solution of atropine.
Storage Conditions
Keep out of reach of children, in a dry, dark place at a temperature of 8 ° C to 15 ° C.
Expiration
3 years.
active substance
Nifedipine
lekarstvennaja tablet form
Health, Russia
